Advanced Chemistry Development, Inc., (ACD/Labs) and Pharma Algorithms, Inc., have joined software development and business resources to provide in silico physicochemical, ADME, metabolism, and toxicology screening and prediction tools.
The companies feature complementary lineups of computational tools, including molecular property prediction, QSAR modeling, ADME and Toxicology prediction, and more. The decision to join forces is the result of the desire of both companies to offer their customers augmented existing tools and new innovations, according to a joint statement.
Until a full integration of products is complete, existing maintenance users of both companies will have access, through their current software package, to the corresponding physicochemical prediction product (including predictions of pKa, logP, logD, and pH-dependent solubility) from the other manufacturer.
Pranas Japertas, Director, Product Development of Pharma Algorithms, said, “We are excited to build on the synergy between the companies to create new integrated capabilities, and expand them to a broader range of applications and customers in both chemical and pharmaceutical research and development. We will work on improving our predictions, and developing new models, as well as augmenting the products already in development.”
“Our customers will benefit immediately from this merger of technologies and scientific expertise within our two companies,” said Daria Thorp, President of ACD/Labs. “We look forward to the new innovations that, combined with the existing products from both companies, will create new comprehensive solutions needed by our customers to further their business.”
The entire Pharma Algorithms product line—including modeling software for ADME, Toxicology, DMSO Solubility, and other products—will be available as part of ACD/Labs’ product portfolio exclusively through ACD/Labs’ extensive international sales and distribution network.
Date: February 9, 2009
Source: ACD/Labs